Wiserlinks Knowledge

  • The world is changing incredibly quickly, business is speeding up, new competitors emerge from other markets. Life is more complex and inter-connected than ever. Leaders have to partner with their peers in order to make these new challenges a success.
  • This blog presents ideas for action.
 

Wiserlinks Knowledge

  • The world is changing incredibly quickly, business is speeding up, new competitors emerge from other markets. Life is more complex and inter-connected than ever. Leaders have to partner with their peers in order to make these new challenges a success.
  • This blog presents ideas for action.
 

Jean-Bernard Girault

Sanofi Throws Caution to the Wind

A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014. REUTERS/Christian Hartmann/File Photo

https://www.bloomberg.com/gadfly/articles/2018-01-29/sanofi-throws-caution-to-the-wind-in-ablynx-takeover | 01/02/2018

Bloomberg Paying a monster price is one way to secure a deal. Sanofi has applied this crude method twice in eight days. The French drugmaker’s reputation as a risk-averse acquirer needs revisiting. Click here to read full article

Continue Reading

Jean-Bernard Girault

Sanofi decides against selling chemical unit Cepia

Sanofi 580

Reuters | 12/05/2017

Reuters Sanofi has given up on the possibility of selling its chemical unit Cepia, a spokeswoman with the French drugmaker said. “I can confirm we have decided to keep the division within the company,” she said, adding that a recent improvement in Cepia’s results, as well as a better outlook for it, was behind this […]

Continue Reading

Jean-Bernard Girault

Sanofi hires advisors for European generic drugs unit sale

Sanofi580

TIMESOFINDIA | 10/04/2017

TIMESOFINDIA French drug maker Sanofi has hired advisers for the sale of its European generic drug business, several sources familiar with matter told Reuters, ahead of an auction process which is expected to start after the European summer. Rothschild, JP Morgan and Morgan Stanley have been asked to organise the long-awaited deal which could be […]

Continue Reading

Jean-Bernard Girault

Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility

Sanofi580

PTCOMMUNITY | 02/03/2017

PTCOMMUNITY Sanofi and Lonza announced that they have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The strategic partnership in the form of a joint venture combines the strong biologics development pipeline of Sanofi with the expertise of Lonza to design, […]

Continue Reading

Jean-Bernard Girault

Drugmaker Ipsen to buy some products from Sanofi for 83 million euros

addiction-71575_960_720

REUTERS | 16/02/2017

REUTERS Drugmaker Ipsen has agreed to buy five consumer healthcare products from bigger French rival Sanofi for 83 million euros ($88 million), in a deal which Ipsen said should boost its profits. The sale arose as part of a requirement from the European Commission to sell off certain assets from an earlier deal between Sanofi […]

Continue Reading

Jean-Bernard Girault

Sanofi, Google parent form $500 million diabetes joint venture

google580

Reuters | 16/09/2016

Reuters French drugmaker Sanofi and Verily, the life sciences unit of Google parent Alphabet Inc, on Monday said they would invest about $500 million in a joint venture combining devices with services to improve diabetes care, an example of growing ties between the pharma and tech sectors. Sanofi said last year it was working on a […]

Continue Reading

Jean-Bernard Girault

Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap

boehringer580

Bloomberg | 16/08/2016

Bloomberg Sanofi agreed to a 22.8 billion-euro ($25.1 billion) asset swap with Germany’s Boehringer Ingelheim GmbH that will bolster the French drugmaker’s business in selling over-the-counter drugs. The companies reached a definitive agreement after announcing exclusive negotiations in December, they said in a statement Monday. The terms are unchanged from the original announcement: Sanofi will trade […]

Continue Reading

Jean-Bernard Girault

Medivation Enters Talks With Sanofi, Others After Raised Bid

Sanofi

Bloomberg | 08/07/2016

Bloomberg Medivation Inc. entered into confidentiality agreements with French drugmaker Sanofi and other parties that have expressed interest in a deal with the U.S. biotechnology company, after earlier rejecting a raised bid from Sanofi. The companies announced the agreement in separate statements on Tuesday, bringing to an end Sanofi’s hostile efforts and turning them into […]

Continue Reading

Jean-Bernard Girault

Sanofi Strikes $2.3 Billion Deal With DiCE Molecules

Sanofi580

Fortune | 18/03/2016

Fortune French drugmaker Sanofi  could pay privately held DiCE Molecules as much as $2.3 billion under a partnership deal announced Wednesday that aims to find new oral medicines to replace injections for certain diseases. The five-year research alliance involves Sanofi paying an initial $50 million to access DiCE’s technology and taking an equity stake in […]

Continue Reading

Jean-Bernard Girault

Sanofi seals double oncology research deals

Sanofi580

Pharmafile | 14/01/2016

Pharmafile Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential new oncology therapies, antibodies and other drugs. Click here to read full article. About Wiserlinks.

Continue Reading